Atossa Genetics Inks Distribution Deal with Fisher HealthCare for ForeCYTE | GenomeWeb

NEW YORK (GenomeWeb News) – Atossa Genetics today announced a distribution deal with Thermo Fisher Scientific's Fisher HealthCare for Atossa's ForeCYTE breast cancer test.

Fisher Healthcare will distribute the ForeCYTE Breast Health device, consisting of Atossa's US Food and Drug Administration-cleared Mammary Aspirate Specimen Cytology Test System, or MASCT, pump and ForeCYTE patient collection kits. ForeCYTE is a risk stratification test for breast cancer.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.